Cargando…
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945404/ https://www.ncbi.nlm.nih.gov/pubmed/31906942 http://dx.doi.org/10.1186/s12931-019-1269-6 |
_version_ | 1783485171723403264 |
---|---|
author | Valenzuela, Claudia Torrisi, Sebastiano Emanuele Kahn, Nicolas Quaresma, Manuel Stowasser, Susanne Kreuter, Michael |
author_facet | Valenzuela, Claudia Torrisi, Sebastiano Emanuele Kahn, Nicolas Quaresma, Manuel Stowasser, Susanne Kreuter, Michael |
author_sort | Valenzuela, Claudia |
collection | PubMed |
description | The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases. This review describes how the nintedanib clinical programme has helped to address some of these challenges. Data from this programme have informed changes to the IPF diagnostic guidelines, the timing of treatment initiation, and the assessment of disease progression. The use of nintedanib to treat patients with advanced lung function impairment, concomitant emphysema, patients awaiting lung transplantation and patients with IPF and lung cancer is discussed. The long-term use of nintedanib and an up-to-date summary of nintedanib in clinical practice are discussed. Directions for future research, namely emerging therapeutic options, precision medicine and other progressive fibrosing interstitial lung diseases, are described. Further developments in these areas should continue to improve patient outcomes. |
format | Online Article Text |
id | pubmed-6945404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69454042020-01-09 Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme Valenzuela, Claudia Torrisi, Sebastiano Emanuele Kahn, Nicolas Quaresma, Manuel Stowasser, Susanne Kreuter, Michael Respir Res Review The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases. This review describes how the nintedanib clinical programme has helped to address some of these challenges. Data from this programme have informed changes to the IPF diagnostic guidelines, the timing of treatment initiation, and the assessment of disease progression. The use of nintedanib to treat patients with advanced lung function impairment, concomitant emphysema, patients awaiting lung transplantation and patients with IPF and lung cancer is discussed. The long-term use of nintedanib and an up-to-date summary of nintedanib in clinical practice are discussed. Directions for future research, namely emerging therapeutic options, precision medicine and other progressive fibrosing interstitial lung diseases, are described. Further developments in these areas should continue to improve patient outcomes. BioMed Central 2020-01-06 2020 /pmc/articles/PMC6945404/ /pubmed/31906942 http://dx.doi.org/10.1186/s12931-019-1269-6 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Valenzuela, Claudia Torrisi, Sebastiano Emanuele Kahn, Nicolas Quaresma, Manuel Stowasser, Susanne Kreuter, Michael Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
title | Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
title_full | Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
title_fullStr | Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
title_full_unstemmed | Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
title_short | Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
title_sort | ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945404/ https://www.ncbi.nlm.nih.gov/pubmed/31906942 http://dx.doi.org/10.1186/s12931-019-1269-6 |
work_keys_str_mv | AT valenzuelaclaudia ongoingchallengesinpulmonaryfibrosisandinsightsfromthenintedanibclinicalprogramme AT torrisisebastianoemanuele ongoingchallengesinpulmonaryfibrosisandinsightsfromthenintedanibclinicalprogramme AT kahnnicolas ongoingchallengesinpulmonaryfibrosisandinsightsfromthenintedanibclinicalprogramme AT quaresmamanuel ongoingchallengesinpulmonaryfibrosisandinsightsfromthenintedanibclinicalprogramme AT stowassersusanne ongoingchallengesinpulmonaryfibrosisandinsightsfromthenintedanibclinicalprogramme AT kreutermichael ongoingchallengesinpulmonaryfibrosisandinsightsfromthenintedanibclinicalprogramme |